Innovent Biologics Balance Sheet Health
Financial Health criteria checks 4/6
Innovent Biologics has a total shareholder equity of CN¥12.4B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to 25.8%. Its total assets and total liabilities are CN¥20.3B and CN¥7.9B respectively.
Key information
25.8%
Debt to equity ratio
CN¥3.21b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥8.63b |
| Equity | CN¥12.43b |
| Total liabilities | CN¥7.87b |
| Total assets | CN¥20.30b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IVBX.F's short term assets (CN¥11.0B) exceed its short term liabilities (CN¥4.1B).
Long Term Liabilities: IVBX.F's short term assets (CN¥11.0B) exceed its long term liabilities (CN¥3.7B).
Debt to Equity History and Analysis
Debt Level: IVBX.F has more cash than its total debt.
Reducing Debt: IVBX.F's debt to equity ratio has increased from 22.7% to 25.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVBX.F has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IVBX.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.